J0578 – Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ0578
- Long description
- Injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy
- Short description
- Inj brixadi, more than 7 day
- Pricing indicator
51Drugs- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1EOther drugs- ASC
- Approved for ambulatory surgical centers
- Added
- April 1, 2024
- Last change
- April 1, 2024 – No change
Frequently asked questions
What is HCPCS code J0578?
J0578 is a HCPCS Level II code for injection, buprenorphine extended release (brixadi), greater than 7 days and up to 28 days of therapy.
Does Medicare cover J0578?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J0570 – Buprenorphine implant, 74.2 mg
- J0571 – Buprenorphine, oral, 1 mg
- J0572 – Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine
- J0573 – Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine
- J0574 – Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine
- J0575 – Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine
- J0576 – Injection, buprenorphine extended-release (brixadi), 1 mg
- J0577 – Injection, buprenorphine extended-release (brixadi), less than or equal to 7 days of therapy
- J0582 – Injection, bivalirudin (endo), not therapeutically equivalent to j0583, 1 mg
- J0583 – Injection, bivalirudin, 1 mg
- J0584 – Injection, burosumab-twza 1 mg
- J0585 – Injection, onabotulinumtoxina, 1 unit
- J0586 – Injection, abobotulinumtoxina, 5 units
- J0587 – Injection, rimabotulinumtoxinb, 100 units
- J0588 – Injection, incobotulinumtoxin a, 1 unit
- J0589 – Injection, daxibotulinumtoxina-lanm, 1 unit
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.